Tag Archive for: OPC

ISA Completes Enrolment in Randomized Double Blind Phase 2 Clinical Trial of ISA101b in HPV16 induced Oropharyngeal Cancer

Study designed to investigate the efficacy and safety of ISA101b added to checkpoint inhibitor therapy in Human Papilloma Virus type 16 (HPV16) induced oropharyngeal cancer (OPC). Trial is part of an extensive clinical development program for ISA101b in a collaboration with Regeneron. Top line interim results anticipated in third quarter of 2023. Oegstgeest, 30 November […]